Drug Trial Radar · NCT00907803
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Jun 2009
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- SIGA TechnologiesIndustry
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH)
- First posted
- May 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
Conditions
- Orthopoxviral Disease
Interventions
ST-246 400 mgDrug
Capsules, 400 mg daily for 14 days
ST-246 600 mgDrug
Capsules, 600 mg daily for 14 days
PlaceboDrug
Capsules, once daily for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Study Participants Who Tolerated a Single Daily Oral ST-246 Dose as Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.Time frame: Days 1 to 14; then 24, 48, 72, 96 and 120 hours and 4 weeks after final dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Apex Research Institute
Santa Ana, California
Orlando Clinical Research Center
Orlando, Florida
Hawaii Clinical Research Center
Honolulu, Hawaii
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.